Amyotrophic lateral sclerosis (ALS) is a severe disease that causes thousands of deaths annually. Current treatments are either limited in effectiveness or not broadly applicable. To discover new options, we conducted a genetics-based screen to identify drugs that could be repurposed for ALS. We analyzed genome-wid...
S. Saez-Atienzar, Luis A. Rojas-Colón, Ruth Chia et al.· npj Digital Medicine· 0 citations
The model’s accurate estimation of disease stages underscores the value of DEBM for patient stratification, offer a promising tool to support clinical trial design and provide a temporal ordering of multiple CSF proteins.
J. D. De Houwer, Wenjie Kang, Renee van Buuren et al.· Alzheimer's Research & T...· 0 citations
Machine-learning stratification of genetic FTD reveals a progressive and a dissociated disease track and provides individualized progression scores that closely track clinical status, enabling smaller, more efficient prevention and early-intervention trials than conventional MRI or NfL markers alone.
M. Soltaninejad, Y. Iturria-Medina, A. Bouzigues et al.· bioRxiv· 0 citations
This Perspective by the LRS-RED consortium discusses methodological, bioinformatic and diagnostic advances in long-read sequencing (LRS) for repeat-expansion disorders, highlighting the potential of LRS to reshape research and clinical practice.
L. Benarroch, J. Pešović, Marzia Rossato et al.· Nature Genetics· 0 citations
Sex and educational attainment significantly affect the development and maintenance of cognitive reserve in individuals with genetic FTD, and underscore the importance of identifying disease-modifying interventions since the presymptomatic stages of the disease.
E. Premi, Damiano Archetti, A. Redolfi et al.· Brain Communications· 0 citations
Frontotemporal lobar degeneration (FTLD) is a common cause of early-onset dementias marked by progressive declines in behavior, cognition, and/or movement. FTLD neuropathologies, including TDP-43 proteinopathies and primary tauopathies, do not have reliable fluid biomarkers for in-vivo diagnosis nor biomarkers that dir...
H. Oh, J. Downer, Connor D. Dietz et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.